跳至主要内容
临床试验/CTIS2024-511618-19-00
CTIS2024-511618-19-00招募中1 期

PDY17892

Sanofi-Aventis Recherche & Developpement0 个研究点目标入组 40 人开始时间: 2024年5月6日最近更新:

试验速览

阶段
1 期
状态
招募中
发起方
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 64(—)
性别
Male

入选标准

  • 未提供

排除标准

  • 未提供

研究者

发起方
Sanofi-Aventis Recherche & Developpement

相似试验

进行中(未招募)
1 期
A study to learn more about how BAY3283142 moves into, through, and out of the body of healthy participants when taken together with atazanavir and to assess the proportion of BAY3283142 that reaches the blood when taken by mouth.MedDRA version: 20.1Level: LLTClassification code: 10054109Term: Non-proliferative diabetic retinopathy Class: 10015919MedDRA version: 23.1Level: PTClassification code: 10064848Term: Chronic kidney disease Class: 100000004857Chronic kidney disease
CTIS2024-510856-11-00Bayer AG15
进行中(未招募)
1 期
Dendritic cell therapy combined with surgery in mesothelioma (ENSURE)Adult patients diagnosed with resectable epithelioid MPM, following first-line chemotherapy.
CTIS2024-514054-70-00Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)14
进行中(未招募)
1 期
A study to test a medicine (fitusiran) for preventing bleeds in people with severe hemophilia who previously received preventive treatment with emicizumabMedDRA version: 20.0Level: LLTClassification code: 10060612Term: Hemophilia A Class: 10010331Hemophilia A
CTIS2022-502414-84-00Sanofi-Aventis Research & Development26
招募中
1 期
A first in human single dose escalation study to investigate the safety, tolerability, pharmacokinetics, and pharmcodynamics of BAY 3389934 compared with placebo.Sepsis associated disseminated intravascular coagulationMedDRA version: 22.0Level: PTClassification code: 10013442Term: Disseminated intravascular coagulation Class: 100000004851MedDRA version: 20.0Level: PTClassification code: 10040047Term: Sepsis Class: 100000004862
CTIS2022-502866-25-00Bayer AG86
进行中(未招募)
1 期
A study to compare how much of the study treatment finerenone gets into the blood when the same amount is taken in one and in two tablets in healthy male participants
CTIS2022-502385-24-00Bayer AG60